Hot Mandate: California Based VC With Accelerator Program Invests In Tech-Driven Companies, Including Digital Health Technologies with AI or Big Data Components

19 Feb

A venture capital firm based in California that invests in early-stage, technology-driven companies has recently started exploring life sciences/healthcare investment opportunities and is considering companies in various sectors. The initial check size of the firm can range from $500K – $2M. The firm also runs a program for those who has already participated in accelerator/incubator programs and want to further initial proofs of concept and early market validation to demonstrate long-term product/market fit, product roadmap, and business model. Companies that have already launched and want to expand go-to-market and reach profitability are welcome to participate in this program as well.

The firm invests in impactful, early-stage technology companies. Within life sciences and healthcare sectors, the firm is interested in medical devices (both 510k and PMA) with a strong data or hardware component and digital health technologies that leverage AI or big data analytics. The firm will not consider traditional therapeutics or diagnostics companies. In terms of disease area, the firm is opportunistic.

The firm can act as either lead or co-investor and is open to working with all kinds of management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

What Successful Partnering Really Looks Like: A Conversation with Neuro20 Technologies

18 Feb

By Rory McCann, Marketing Manager & Conference Producer, LSN

When fundraising executives seek out a successful partnering experience, so many define success with deals and checks. At Life Science Nation, we frequently hear success stories that do end with capital and funding, but many do not. Instead, these stories touch on the benefits of successful partnering that impact company growth and bottom line in other ways, often the details that are taken for granted when seeking strategic partners.

Neuro20 Technologies is one such success story. They attended their first digital RESI conference looking for capital but came out with so much more. Listen to their story, and sign up for Digital RESI JPM to learn more from the Neuro20 Technologies team and start your partnering success story!

Last Chance to Apply for the Innovator’s Pitch Challenge

18 Feb

By Joey Wong, Investor Research Analyst, LSN

One of the most powerful features at Healthtech Partnering Week, March 15-19, is the Innovator’s Pitch Challenge. This is a valuable opportunity for fundraising CEOs to showcase their technologies to conference attendees and pitch live to a panel of active investors and industry experts. Each conference throughout the week will host its own Innovator’s Pitch Challenge to ensure best fit for sector and technology. Learn about each conference and determine the best fit for you!

Accepted companies will each be provided with a dedicated landing page on the conference’s Live Agenda, which will host a full-length pitch video, pitch deck, executive summary and any other supplementary materials that are submitted. Companies are also invited to participate in a live Q&A session, which will include a quick elevator pitch, followed by questions and insights from a panel of active investors and industry experts.

This is a valuable opportunity to not only boost exposure among all the conference attendees, but also connect and speak directly with active investors and industry experts in the space. If you are a fundraising CEO, you do not want to miss this opportunity!

The last day to apply for the Innovator’s Pitch Challenge is this Friday, February 19. Be sure to submit your applications before then!

Apply for RESI IPC
March 15 – 17
Apply for 4D Meets AI IPC
March 18 – 19
Apply for LHI IPC
March 18 – 19

Getting it Right from Pitch to Partner

18 Feb

By Karen Deyo, Director of Investor Research, Israel BD, LSN

As each Life Science Nation event approaches, we spend a lot of time and effort to help startups achieve the best possible outcome through partnering. We have published many articles detailing why partnering is important, how to get ready for your outreach, how to get as many meetings as possible and how to prepare for them.

As we gear up to launch Digital RESI partnering next week, we are offering a free tutorial to help founders make the most of the partnering experience. But what steps can you take to make your meeting successful, to improve your chances of a follow up meeting? Here are a few tips that can help!

  1. Know your audience.

We frequently give this advice, both when requesting meetings and when preparing for them. Your meeting will be different, depending on whether you are speaking to a VC, an angel group or a strategic partner. What are they looking for? This can give you the key to making yourself stand out. Make use of online resources to know the investor with whom you are meeting, the organization and their portfolio companies, such as their website, LinkedIn or Crunchbase, among others. The more info you have, the better you can focus on what about your company will spark their interest.

  1. During the meeting, make it a discussion – not a presentation.

In our experience, companies that approach meetings as a discussion with the investor, as opposed to a pitch running through their deck, meet with better responses. Investors see a lot of pitches, and you want to be able to translate your enthusiasm for your company – this does not translate well when simply running through your deck. Engage the investor in a conversation and make it dynamic. However, remember to be grounded: it is important to be passionate, but be realistic about your technology. Not every company is founded on first-in-class science. Improvements to current treatment paradigms can be just as successful and may be more attractive to some investors due to the decreased risk, so don’t oversell yourself.

  1. Know which areas of your company/technology to highlight.

No one knows your company, or your story, better than you. Give the investors a concise (but complete) overview of your company. You know what makes your company stand out, whether it is the story behind the company, the technology, the team, or the application – make sure to highlight this. Also, make sure the investor knows what milestones you have already achieved and, more importantly, how much you are raising and what milestones you plan to hit with these funds.

  1. Know what questions to ask the investor.

The investor will certainly ask you questions that you should be prepared to answer, but you should also think about what questions you want to ask the investor. Gaining an investor is like entering a long-term relationship – you want to make sure that you can work well together, potentially for years to come. In addition, many investors are more than just financial contributors. It is key to find out how involved the investor chooses to be after investing: do they take a board seat? Will they leverage their network or connections for you? For a strategic partner, do they have an infrastructure that could benefit your development? As with the previous tips, this is where knowing your audience can play a big role, as your questions will change depending on the investor. You may ask a traditional VC about their desired timeline to exit, but you would likely ask a Corporate VC about how connected the parent company is to their deals.

The more prepared you are, the greater your chance of success. Fundraising is not only a numbers game, but it can also be a full-time job. By doing what you can to shorten the fundraise, you can increase your time to focus on the most important aspect of your job – building a successful company!

Sign up for our free partnering tutorial, Tuesday, February 23, 12 PM EST.

There is still time to sign up for Healthtech Partnering Week at the early-bird rate. Sign up by February 19 and SAVE!

Hot Investor Mandate: Family Office-Backed Asia VC Seeks Early-Stage Opportunities in Therapeutics & Medical Devices Across The Globe

18 Feb

A biotech early stage investment firm headquartered in Asia invests from an evergreen fund backed by a family office. The firm has a fund size of $50M and an average ticket size range from $250K to $1M. The firm mainly focuses on early-stage biotechnology and medical device companies and is looking to invest in seed to pre-A round.

The firm is looking for new investment opportunities across a wide spectrum of life science sectors. The current pipeline includes biotechnology platforms, medical devices, therapeutics and service platforms.

The firm does not have any specific requirements for companies and their management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA-Based Investment Firm Interested in Companies Working on the Intersection of Biology, Technology, and Data Science

18 Feb

A venture capital firm based in USA invests in companies dedicated to working on the intersection of biology, technology, and data science. The firm is focused on early-stage investments from Seed to Series A and also dedicates funds to follow-on investment. Initial check sizes are usually between $1-2M but can fall outside of this range on a case-by-case basis. The firm will consider global opportunities.

The firm invests in the intersection of biology, technology, and data science and the areas of interest fall beyond traditional sectors. The firm is focused on (1) technology driving biology (miniaturization, automation, data sciences); (2) biology as technology (synthetic biology, genetic engineering, stem cells); (3) biology beyond healthcare (agriculture, chemicals/industrials, consumer). The firm will consider cutting edge therapeutics/drug development and platform technologies and diagnostics, is not interested in traditional medical devices or digital health.

The firm focuses on privately owned, early stage companies and is open to working with all types of management teams. The firm likes to step in early and prefers to act as the lead investor, but is open to co-investing as well.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Europe Based VC Invests Up to €10M Across All Life Science Sectors, Seeking Companies in Central & Western Europe

18 Feb

A venture capital firm with offices in Western Europe makes equity investments in early-to-late stage therapeutics, diagnostics, and medical devices companies. The firm can generally allocate between €2M to €10M. The firm only invests in companies that are based in Central and Western Europe. The firm is actively seeking new investment opportunities.

The firm is very opportunistic in the life sciences space. The firm focuses on therapeutics, diagnostics, and medical devices companies and is also interested in digital health. The firm targets therapeutic products in clinical trials or which are ready to enter Phase I, and medical devices which are CE Mark ready.  The firm is very opportunistic in terms of subsectors and indications. However, the firm does not invest in cosmetics and dental devices.  The firm strongly prefers companies developing products that address a highly unmet medical need. In digital health, the firm prefers to invest in products that have or are pursuing regulatory approval to monitor or treat a condition in which there is an unmet medical need. Generally these products will include both a hardware and a software component.  The firm is not interested in consumer or lifestyle health products.  The firm invested in companies that are developing small molecule therapeutics for women’s health and diagnostics targeting autoimmune, allergic, eye, inflammatory, liver diseases, and also in company developing device to treat prostate cancer.

The firm plays the role of lead or co-lead investor in the large majority of its financing rounds. The firm requires a board seat in its portfolio companies. The firm seeks a company with a strong and qualified management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.